freedomdiagnosticstesting.com publishes a public verification portal. Any test attributed to this lab can be looked up and confirmed directly with the lab — so this result doesn't rest on our review alone.
This certificate carries no lookup code.
This is a purity and identity analysis. Sterility, endotoxins, and heavy metals were not screened — a high purity figure says nothing about those.
Label 20 mg · Lab measured 21.02 mg
105% of label, basis not stated — shown as printed. Reconstituted with 2 mL, a 50-unit draw holds 5.3 mg using the measured mass, against 5 mg on the label — 5% more.
One vial from this lot was weighed by the laboratory, not yours. This page reports what the certificate says; it does not recommend a dose.
Independent HPLC purity analysis of Ipamorelin/Tesamorelin from OROS Research, performed by freedomdiagnosticstesting.com on February 9, 2026. Reported purity: 99.204%. Net content: 21.02 mg against 20 mg labeled (105% of label). Batch 1427354. Sample source: shop-provided. Certificate of analysis attached.
| Lot | Tested | Lab | Purity | vs label | Status |
|---|---|---|---|---|---|
| 1624882 | 28 Feb 2026 | freedomdiagnosticstesting.com | 99.22% | 107% | Unverified |
| 1536499 | 17 Feb 2026 | freedomdiagnosticstesting.com | 99.905% | 104% | Unverified |
| 1245860 | 1 Feb 2026 | freedomdiagnosticstesting.com | 99.572% | 97% | Unverified |
| 1247385 | 1 Feb 2026 | freedomdiagnosticstesting.com | 99.923% | 108% | Unverified |
| 1136576 | 9 Jan 2026 | freedomdiagnosticstesting.com | 99.703% | 99% | Unverified |
| 853822 | 8 Dec 2025 | freedomdiagnosticstesting.com | 99.808% | 114% | Unverified |
| 795263 | 15 Nov 2025 | freedomdiagnosticstesting.com | 99.62% | 142% | Unverified |
| 776843 | 7 Nov 2025 | freedomdiagnosticstesting.com | 99.42% | 103% | Unverified |
Batches this shop has published a certificate for, newest first. A lot whose printed value cannot identify a batch is not listed.
Submit your third-party lab test to help the community verify purity claims. Every report is reviewed before publication.
Community discussion